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Abstract
Background: Fructose-1,6-bisphosphatase deficiency is a rare inborn error of metabolism affecting gluconeogenesis
with only sporadic reports on its molecular genetic basis.
Results: We report our experience with mutation analysis in 14 patients (13 families) with fructose-1,6-bisphosphatase
deficiency using conventional Sanger sequencing and multiplex ligation-dependent probe amplification analysis,
and we provide a mutation update for the fructose bisphosphatase-1 gene (FBP1). Mutations were found on both
chromosomes in all of our 14 patients including 5 novel mutations. Among the novel mutations is a 5412-bp
deletion (c.-24-26_170 + 5192del) including the entire coding sequence of exon 2 of FBP1 that was repeatedly
found in patients from Turkey and Armenia which may explain earlier poorly defined findings in patients from
this area. This deletion can be detected with specific primers by generation of a junction fragment and by MLPA
and SNP array assays. MLPA analysis was able to detect copy number variations in two further patients, one
heterozygous for a deletion within exon 8, another heterozygous for a novel deletion of the entire FBP1 gene.
Conclusions: Based on our update for the FBP1 gene, currently listing 35 mutations worldwide, and knowledge
of PCR conditions that allow simple detection of a common FBP1 deletion in the Armenian and Turkish population,
molecular genetic diagnosis has become easier in FBP1 deficiency. Furthermore, MLPA analysis may plays a useful role
in patients with this disorder.
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Background
Fructose-1,6-bisphosphatase (FBP1) deficiency [OMIM:
229700], first described in 1970 [1], is an inborn
error of gluconeogenesis. Patients present with ke-
totic hypoglycemia and lactic acidosis triggered by
catabolic episodes such as prolonged fasting and/or
febrile infections [2]. Laboratory findings may include
hyperalaninemia, hyperketonemia, an increased lactate/
pyruvate ratio, an elevated plasma concentration of uric
acid, glyceroluria [2], and pseudo-hypertriglyceridemia [3].
FBP1 deficiency is generally believed to be very rare with
an estimated incidence between 1 : 350,000 and <1 :
900,000 in the Dutch and French population, respectively
[4, 5]; but it may be more frequent in populations with a
higher rate of consanguinity.
FBP1 deficiency is inherited in an autosomal recessive
way. It is caused by mutations within the FBP1 gene
(OMIM: 611570) which spans approx. 31 kb on chromo-
some 9q22.2-q22.3 and consists of 8 exons [6]. To date,
only a small number of mutations has been published
and among them, c.959dupG has been reported to be
the most common one in Caucasians but also in patients
from Japan and China [5, 7–9].
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We report results of mutation analysis of our labora-
tory, describe how we have characterized a common
exon 2 deletion detected in patients with Turkish or
Armenian ethnic background, and provide PCR condi-
tions for verification of this deletion which is otherwise
not detectable by standard sequencing techniques.
Finally, we show for the first time that MLPA analysis may
play a useful role in the diagnosis of FBP1 deficiency.
Methods
Fourteen patients with FBP1 deficiency from 13 families
with typical clinical and laboratory results were diagnosed
in our laboratory between 2006 and 2014 (Table 1). Not all
of them had enzymatic studies performed but all parents
gave their informed consent to search for the molecular
basis of the disease of their children and to be investigated
for their own carrier status. In all of them, all 8 exons and
adjacent intronic segments of the FBP1 gene were amplified
by PCR and sequenced according to standard Sanger tech-
niques (primer sequences and PCR conditions available
upon request). In those patients in whom we assumed a de-
letion of exon 2 (the first coding exon), we were able to
generate a junction fragment with primers 5′-taaaggtttccgc-
gattcac-3′ (sn) and 5′-gaccatcctggccaacac-3′ (asn). Results
of sequencing studies were compared to our FBP1 refer-
ence sequence NM_001127628.1. Nomenclature for the
description of sequence variants follows the recommenda-
tions of the Human Genome Variation Society [10]. The
bioinformatic tools Polyphen-2 [11] and Mutation Taster
[12] were used to predict effects of sequence aberrations.
In those patients in whom the diagnosis of FBP1 defi-
ciency was not confirmed by Sanger sequencing and the
detection of 2 biallelic mutations within FBP1, MLPA
analysis was performed. We used the reaction mixtures
SALSA MLPA probemix P255-B1 ALDOB-FBP1 (MRC
Holland, Amsterdam, The Netherlands) according to the
manufacturer’s recommendations. Acquired data were
normalized with 3–5 control DNA samples isolated in
our laboratory. Calculations were performed with the
SeqPilot software for genetic analyses version 4.1.2 (JSI
Medical Systems, Ettenheim, Germany). SNP array ana-
lysis was performed using the Genome-Wide Human
SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) eval-
uated by the Genotyping Console software version 4.1.
Results and discussion
Conventional Sanger sequencing analysis of all coding
exons allowed the diagnosis of FBP1 deficiency in 9 out of
Table 1 Ethnic origin and molecular genetic findings of the 14 patients of this study
Patient
number
SANGER sequencing results MLPA results
Ethnic origin Mutation Mutation effect Deletion of … Reference for first report
1 Armeniaa c.-24–26_170 + 5192delb p.0? homo exon 2 (homo) This study
2 Turkeya c.-24–26_170 + 5192delb p.0? homo exon 2 (homo) This study
3 Turkeya c.-24–26_170 + 5192delb p.0? homo exon 2 (homo) This study
4 Pakistan c.841G > A p.(E281K)c homo n.a. [3]
5 Pakistan c.841G > A p.(E281K)c homo n.a. [3]
6 Pakistan c.881G > A p.(G294E) homo n.a. [18]
7 Pakistan c.841G > A p.(E281K)c homo n.a. [3]
8-1 Germany c.490G > A p.G164S homo n.a. [8]
8-2 Germany c.490G > A p.G164S homo n.a. [8]
9 Germany c.704dupC p.(D236Rfs*2) homo n.a. [7]
10 Turkey / c.359C > T p.(P120L) hetero n.a. This study
Turkey c.881G > A p.(G294E) hetero n.a. [4]
11 Turkey c.841G > A p.(E281K)d homo n.a. [4]
12 Germany / c.619G > C p.(G207R) hetero - This study
Germany n.d. ? ? exon 8 (hetero) This study
13 Germany / c.959dupG p.(S321Ifs*13) hetero - [14]
Germany deletione ? hetero exons 1–8 (hetero) This study
asee Additional file 1: Fig. S1
bonly detectable when sequencing a junction fragment with specific primers
c,drepresents different haplotypes
elong range deletion (larger than exon 08) suggested by haplotype analysis
n.a., not applied
n.d., not detected
Novel mutations are shown in bold
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Table 2 Summary of the 35 FBP1 mutations reported in fructose-1,6-bisphosphatase deficiency
Nucleotide change Amino acid change Ethnic origin Referencea
Single nucleotide changes
Exon 2 c.88G > T p.(E30*) Japan [8]
Exon 4 c.359C > T p.(P120L) Turkey This study
Exon 5 c.472C > T p.(R158W) France [5]
c.490G > A p.G164S Japan/South Korea/? [5, 8, 19]
c.530C > A p.A177D Japan [8]
Exon 6 c.581 T > C p.(F194S) Japan [20]
c.619G > C p.(G207R) Germany This study
c.639C > G p.(N213K) ? [5, 7]
c.648C > G p.(Y216*) Sweden [18]
c.685C > T p.(Q229*) Morocco [5, 15]
Exon 7 c.778G > A p.G260R Pakistan/Sweden [18, 21]
Exon 8 c.841G > A p.(E281K) Pakistanb/Turkeyb [3]
c.841G > T p.(E281*) Saudi Arabia [22]
c.851C > G p.(P284R) Japan [20]
c.881G > T p.(G294V) [7]
c.881G > A p.(G294E) Sweden/Pakistan [18/3]
Deletions
Complete Deletion of the FBP1 genec p.0? Sweden [18]
Complete Deletion of the FBP1 gened p.0? Germany This study
Exon 2 c.-24–26_170 + 5192del p.? Turkey/Armenia This study
c.35delA p.N12Tfs*2 Turkey/Germany (?) [21]
c.48delC p.(F17Sfs*15) France [5]
Exon 3–7 complete deletion p.? ? [5]
Exon 6 c.616_619delAAAG p.(K206V*70) Turkey [23]
c.660delT p.(F220Lfs*57) Turkey [24]
Exon 7 c.807delG p.(K270Rfs*7) ? [7]
Exon 8 deletione p.? Germany This study
c.838delT p.Y280Tfs*25 South Korea [19]
c.966delC p.D323Tfs*7 Iran [21]
Insertions/Duplication
Exon 2 c.114_119dupCTGCAC p.(C39_T40dup) Saudi Arabia [22]
Exon 6 c.704dupC p.(D236Rfs*2) ? [7]
Exon 8 c.865dupA p.(M289Nfs*45) Greece [5]
c.959dupGf p.S321Ifs*13 Japan/Europe/China [5, 7–9]
Indel
Exon 7 c.731_738delins20 p.(R244_Y245delins6) Turkey [5]
Splicing
Intron 4 c.427–1del p.(K143_P189del) ? [5]
Intron 7 c.825 + 1G > A p.? ? [5]
aslash (/) refers to slash in column ‘ethnic origin’
bwith different haplotypes
ctogether with deletion of FBP2 and parts of ONPEP (hg19 chr9:g.(97295486_97300076)_(97571249_97571455), approx. 0.28 Mb)
dtogether with deletion of FBP2 (hg19 chr9:g.(97281072_97289359)_(97419146_97420857), approx. 0.13 Mb)
eexon 8 only according to additional SNP array analysis (hg19 chr9:g.(97364379_97365560)_(97365642_97365985))
foriginally named c.960_1insG
Novel mutations are shown in bold
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the 14 patients (patients 4–11 in Table 1). These patients
were found to be homozygous or compound heterozygous
for mutations within FBP1. Among them, we found two
novel missense mutations, p.(Pro120Leu) and p.(Gly207Arg)
in exons 4 and 6, respectively, each in single families.
Each of these two amino acid positions are part of
highly conserved stretches of amino acids. Polyphen-2
predicts both of these 2 missense mutations to be
‘probably damaging’ (score 1.00). Mutation Taster clas-
sifies them as ‘disease-causing’ (with probability scores
of 0.99999999999648 and 0.999999999878082, resp.).
To our knowledge, p.(Pro120Leu) has never been reported
to databases before; according to the ExAC database, the
p.(Gly207Arg) variant has been observed in 10 European
(non-Finnish) individuals in the heterozygous state with
an allele frequency of 0.0001498 [13].
To date, only a limited number of FBP1 mutations has
been detected worldwide; our study brings up the total
number to 35 (Table 2). Only few mutations have been
found that do not have the characteristics of a private
mutation. Among them is c.959dupG, originally found
in the Japanese population [14] that has also been detected
in patients from Europe [5] and North America [7], and
recently also in patients from China [9]. Another example
is c.841G > A which has been detected in several unrelated
patients from Pakistan [3] but also, with a different haplo-
type, in patients from Turkey [this study]. Furthermore,
c.685C > T has repeatedly been found in seemingly unre-
lated families from Morocco [5, 15].
In two of our patients, #12 and #13, only one mutation
was detected by conventional Sanger sequencing analysis,
however, haplotype analysis in the parents of patient #13
already suggested a long range deletion of the paternal
allele (detailed results not shown). Of note, in 3 consecu-
tive unrelated patients, one from Armenia and two from
Turkey, no PCR product could be generated for exon 2 of
the FBP1 gene. This observation prompted us to further
investigate these patients. This was of particular interest
since earlier reports on mutations in FBP1 had speculated
that deletions within exon 2 (which at that time was
termed exon 1) are common in the Turkish population,
although the authors were not able to further characterize
them [7]. Since we assumed the presence of a long-range
deletion in these 3 patients, extensive modification of pri-
mer pairs was performed with the aim to generate a PCR
product of acceptable size to be visible on polyacrylamide
gel electrophoresis and eventually allowed the successful
generation of a junction fragment (Fig. 1). All 3 patients in
Fig. 1 Characterization of a common long-range deletion of the FBP1 gene. A junction fragment including a deletion in the range of exon 2
was generated from DNA of patient 1. The result of the sequencing reaction is shown. The novel deletion (indicated in red) comprises 26 bp
of intron 1, another 24 bp of the untranslated region (5′-UTR) before the ATG initiation codon of exon 2, the entire coding region of 170 bp
of exon 2 (blue), and another 5192 bp of intron 2. The bold black lines (indicated by the asterisks) describe the position of the MLPA probes for
exon 2 used in this study
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whom exon 2 could not be amplified with standard
primers were thus found to be homozygous for a large
deletion spanning 5412 base pairs and including the
entire coding sequence of exon 2 (c.-24-26_170 +
5192del). All these patients were seemingly homozygous
for the following polymorphisms that are all known
from databases and have also been detected in our lab
both in healthy and diseased controls: c.426 + 7T
[rs8192689], c.567 + 31G [rs3739747], c.651T [p.(=),
rs1042144], c.653A [p.(Arg218Lys), rs1769259], c.705 +
14C [rs2297084], c.960G [p.(=), rs1769257], c.*213T
[rs9695]. Segregation analysis showed that all the pa-
tients’ parents carried the deletion in the heterozygous
state and indicated that a single haplotype was associated
Control
Pt 2
Pt 12
Pt 13
a
b
c
d
Exon         1      2      3      4       5      6       7      8    
Fig. 2 Results of MLPA analysis in FBP1 deficiency. Results are shown for a control sample (a), patient 2 (b), patient 12 (c), and patient 13 (d). For
patient details see Table 1. Each panel shows the results for the intensity of probe amplification for the eight exons of FBP1. Patients’ results are
depicted in green bars, while means (± SD) of concomitantly measured controls are shown in blue. The presentation below these bars shows the
deviation of patients’ results as a percentage of control with the dotted line representing 0, and the horizontal red bars −25 %, +25 %, and +50 %,
respectively. Note the missing probe amplification for exon 2 in patient 2 which is in line with homozygosity for the novel exon 2 deletion. Patient 12
shows a signal intensity for exon 8 of approximately 50 % suggesting heterozygosity for a deletion. In patient 13, signal intensities for all 8 exons are
reduced to approximately 50 % of controls suggesting heterozygosity for a deletion of the entire FBP1 gene
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with this deletion (Additional file 2: Fig. S3). These results
are compatible with our assumption that this mutation
represents a founder mutation in the Armenian and Turk-
ish population. We believe that this mutation plays quite
an important role in that geographical area since, in
addition to Herzog et al. [7] (see above) who supposed de-
letions in exon 2 in patients originating from Turkey, also
Lebigot et al. [5], in a most recent study, reported exon 2
deletions by gene dose assays in Turkish patients; again,
no further details regarding its length and location were
provided. Furthermore, a preliminary communication
from Turkey reported a relatively high number of FBP1-
deficient cases from this region and, again, mentioned
poorly defined exon 2 deletions [16]. It may therefore be
speculated that the deletion characterized in detail in this
paper is the same deletion as originally mentioned by sev-
eral authors [5, 7, 16] and it may be concluded that this de-
letion of exon 2 is a relatively common cause of FBP1
deficiency in patients of Turkish and Armenian origin. Pa-
tients with this ethnic background should primarily be
screened for this deletion and Sanger sequencing is now
possible when using specific primers that allow sequencing
of a junction fragment.
Such long-range deletions and other variations in copy
number, particularly when present in the heterozygous
state, may escape conventional sequencing techniques.
Multiplex ligation-dependent probe amplification (MLPA),
originally described in 2002 [17], is increasingly used for
the targeted screening for copy number variations and has
recently become commercially available for the FBP1 gene.
Therefore, we applied this method to the five patients in
whom we had not arrived at a diagnosis with standard se-
quencing techniques. Patients #1 to #3 all showed the typ-
ical pattern of homozygosity for an exon 2 deletion
(Fig. 2b), thus, MLPA analysis was in accordance with our
sequencing results. In patient #12, we found that MLPA for
exon 8 was diminished to approximately 50 % of normal
controls (Fig. 2c). Therefore, heterozygosity for a long-
range deletion was supposed, which was subsequently
confirmed by SNP array analysis (Table 2). In patient
#13, heterozygosity for a deletion on the paternal allele
was confirmed and we could show that the deletion affects
all 8 exons (Fig. 2d). Furthermore, we were able to demon-
strate by SNP array analysis that the mutation in pt #13 af-
fecting the entire FBP1 gene is not identical to the one
reported by Asberg [18] who described a patient with a
deletion of the entire FBP1 gene together with the neigh-
boring FBP2 and ONPEP genes (Table 2).
Conclusions
In summary, we provide an update of the 35 FBP1 muta-
tions reported to date, present PCR conditions that
allow detection of a common FBP1 mutation in the
Armenian and Turkish population, and more generally,
demonstrate for the first time the useful role of MLPA
analysis in the diagnosis of FBP1 deficiency.
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